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Abstract: Treat-to-target (T2T) and dose taper-
ing after obtaining the therapeutic objective
(called ‘‘treat-to-budget’’-T2B-in this Commen-
tary) are the two most commonly used thera-
peutic strategies in rheumatoid arthritis. In
theory, both strategies could add value to the
healthcare system, although they are focused on
different objectives: T2T strategy improves out-
comes but increases short-term costs, while the
cost savings obtained through T2B are associated
with higher relapse rates. The systematic imple-
mentation of both strategies must be founded on
solid evidence of their effectiveness and effi-
ciency. However, the level of evidence between
guidelines and individual studies is inconsistent
for both strategies and the number and the
quality of cost-effectiveness analyses is scarce.
Raising the level of evidence requires a move
from generalization to individualization by
conducting randomized clinical trials that assess
each of the many strategies that fall under the
umbrella of the overall T2T and T2B concepts. In
addition, such studies should consider the ther-
apeutic goals and impact of the disease from the
perspective of individual patients, which is only
possible by promoting shared decision-making.
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Key Summary Points
Treat-to-target (T2T) and dose tapering
after obtaining the therapeutic objective
(‘‘treat-to-budget’’-T2B-) are the two most
commonly used therapeutic strategies in
rheumatoid arthritis.
The systematic implementation of both
strategies must be founded on solid evidence
of their effectiveness and efficiency.
However, the level of evidence between
guidelines and individual studies is
inconsistent for both strategies and the
number and the quality of cost-
effectiveness analyses is scarce.
Raising the level of evidence requires a move
from generalization to individualization by
conducting randomized clinical trials that
assess each of the many strategies that fall
under the umbrella of the overall T2T and
T2B concepts.
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Rheumatoid arthritis (RA) is a chronic
inflammatory joint disease characterized by its
high prevalence and substantial impact on
society and health services. Over the last dec-
ade, the systematic use of reliable tools for
clinical evaluation, the development of targeted
synthetic disease-modifying antirheumatic
drugs (tsDMARDs), and the implementation of
new therapeutic strategies have all contributed
to a significant improvement in the prognosis
of RA [1]. At present, the two most commonly
used treatment strategies are treat-to-target
(T2T) and dose tapering after obtaining the
therapeutic objective.
The aim of T2T is to achieve clinical remis-
sion or at least a low level of disease activity.
The implementation of T2T requires an early
diagnosis and must be based on a joint decision
made by the doctor and the patient. Disease
activity must also be tightly controlled through
regular treatment adjustments to reach the
therapeutic target. Tapering involves reducing
the dose, or increasing the interval between
doses, in patients who have achieved remission
or a low disease activity. Tapering aims to
maintaining the therapeutic goal but at the
same time decreasing the risk of adverse effects
and the cost of treatment, thereby contributing
to the sustainability of healthcare systems, so
this strategy could also be dubbed as ‘‘treat-to-
budget’’ (T2B). The literature contains excellent
reviews of both strategies [2–4].
In theory, the combined use of T2T and T2B
could add value to the healthcare system.
According to Porter’s well-known definition of
value, healthcare systems should seek the best
health outcomes achieved per dollar spent [5].
Each of the strategies helps improve one of the
two components in Porter’s equation, but they
can also have a negative impact on the other
component. There is evidence suggesting that
the T2T strategy improves outcomes, but
increases short-term costs; [6] while on the
other hand, the cost savings obtained through
T2B are associated with a higher relapse rate [7]
(Table 1). Given this, the clinical and economic
impact of using both strategies, either sepa-
rately or in combination, cannot be analyzed
independently. The total cost (not just the drug-
related cost) and clinical outcomes of each
strategy must be compared before drawing
conclusions about their value. In other words,
the cost-effectiveness of T2T and T2B must be
analyzed to determine their value.
Most publications into RA management
support the use of T2T over that of the usual
treatment [2]. The T2T approach has been
adopted by the American College of Rheuma-
tology (ACR), the European League Against
Rheumatism (EULAR) and the Asia Pacific Lea-
gue of Associations for Rheumatology (APLAR)
[4], although the level of evidence (LoE)
between the guidelines is inconsistent. For
instance, the LoE in the EULAR guidelines lies
between 1a and 2b, depending on the type of
recommendation [8], while it is low or moder-
ate in the ACR guidelines, depending on the
type of patient [9]. An exhaustive review by the
National Institute for Health Research UK con-
cluded that there was mixed evidence for T2T
and only observed clinical benefits in specific
patient groups (early RA) for some outcomes
[10]. The discrepancy between the guidelines
and various individual studies that compare
T2T against routine treatment should not come
as a surprise. These differences can be explained
by the high heterogeneity of the studies, which
assessed different types of patients and included
distinct study designs, treatment regimens,
response criteria, and variables.
T2T increases short-term healthcare costs,
however very few researchers have assessed the
strategy’s efficiency [11] and even those were
low-quality studies [10]. A robust evaluation of
efficiency would need to analyze the incre-
mental cost-effectiveness ratio [expressed as
additional cost per quality-adjusted life year
(QALY) gained] for each of the many treatment
regimens that fall under the T2T concept in
order to check if the cost per QALY gained lies
below commonly accepted cost-effectiveness
thresholds.
With respect to tapering, the relapse rate
depends on the dose reduction regimen, but it is
often above 30%, one year after treatment [7].
Different studies show that better outcomes are
obtained in patients in sustained remission for
at least 6 months and dose reduction or an
increase in dosing interval are preferable to
treatment discontinuation [12]. It is also known
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that when relapse occurs, patients respond well
to reintroduction of the same drug [12]. It
should be noted that most of the evidence on
tapering comes from observational studies with
a small sample size and only a third are based on
randomized clinical trials [7]. A recent single-
blind, randomized clinical trial found relapse
rates of 33% and 43% (p = 0.17) in the first year
after reducing the dose of TNF inhibitors and
conventional synthetic DMARDs (csDMARDs),
respectively [13]. While it is widely accepted
that higher doses of biological agents are asso-
ciated with a greater risk of infection, it is
remarkable that tapering studies do not evalu-
ate the decrease in adverse effects before and
after applying the strategy, which proves very
revealing about the main aim of dose reduction,
which seems to focus mostly on impact on
efficacy.
The level of evidence and strength of rec-
ommendation for the T2B approach in the main
guidelines (ACR, EULAR) is at best moderate
(2b) and there are no indications as to which is
the most appropriate tapering strategy [3, 8, 9].
In contrast to the T2T strategy, which is less
widely implemented [14] despite support from a
greater LoE, the degree of T2B implementation
is relatively high (Table 1) [15, 16], probably
because it is easier to put into practice and
requires less resources than T2T.
Tapering studies feature a broad hetero-
geneity in dose reduction regimes, follow-up
time, and patient type [7]. There is therefore a
need to assess the effectiveness of each dose
reduction schedule for each specific drug, while
continuing to make progress in the study of
predictors of low disease activity and remission
to identify which patients might benefit the
most from tapering. To date, very few anti-
rheumatic drugs include information on dose
reduction results in their summary of product
characteristics [17].
Several studies have estimated the direct
savings in drug costs derived from tapering, but
practically none of them have evaluated its
cost-effectiveness [18]. Given that dose reduc-
tion tends to increase the rate of relapses, future
studies should contemplate a decremental cost-
effectiveness analysis, whose results are expres-
sed as cost saved per quality-adjusted life year
lost. These results should help decide whether
the savings associated with the strategy offset
the potential for clinical deterioration [19]. One
study used this approach and reported a savings
of €390,493 per QALY lost and therefore con-
cluded the strategy was highly effective [20].
However, we cannot assume this finding is true
for all tapering regimes because in the given
study the dose reduction was not accompanied
by a significant increase in relapses, which is
unusual compared to most other tapering
studies [7].
We are currently experiencing a trend for a
convergence between evidence-based and
patient-centered medicine [21]. The adoption of
strategies such as T2T and T2B should fulfill
Table 1 Some differentiating characteristics of treat-to-target and treat-to-budget strategies
Treat-to-target Treat-to-budget
Main focus Patient Healthcare system (payer)
Main objective Improves outcomes Reduces costs
Potential negative consequence Increases cost Reduces effectiveness
Scope of the strategy Wide (diagnosis, patient care, treatment, etc.) Narrow (drugs)
Level of evidence Moderate–High Low–Moderate
Degree of implementation Low–Moderate Moderate–High
Evidence of cost-effectiveness Scarce Scarce
Value approach Incremental cost-effectiveness Decremental cost-effectiveness
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both objectives, adding value to individual
patients and healthcare systems. However, the
systematic implementation of these strategies
must be founded on solid evidence of their
effectiveness and efficiency. Raising the level of
evidence requires a move from generalization to
individualization by conducting randomized
clinical trials that assess each of the many
strategies that fall under the umbrella of the
overall T2T and T2B concepts. In addition, such
studies should take into account the therapeutic
goals and impact of the disease from the per-
spective of individual patients, which is only
possible by considering their perspective and
promoting shared decision-making.
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